Aardvark Therapeutics Hit With Investor Class Action Over ARD-101 Trial Halt

If you bought shares of Aardvark Therapeutics (NASDAQ: AARD) at some point and watched the stock tumble, you might want to pay attention to this. Pomerantz LLP, a law firm that specializes in securities fraud cases, has filed a class action lawsuit against the biotech company and several of its officers and directors, alleging they misled investors about their most important drug candidate.

The lawsuit centers on ARD-101, Aardvark's lead experimental treatment. According to the complaint, the company made false or misleading statements about ARD-101 — and things came crashing down when Aardvark first voluntarily paused its Phase 3 clinical trial (that's the large, late-stage human trial required before a drug can go to market) and then received a full clinical hold from the FDA. A clinical hold is basically the FDA pumping the brakes hard — it means the company cannot continue giving the drug to patients until serious concerns are resolved. Stock prices tend to not love that kind of news.

Read more HCW Biologics Files to Register 1.24M Shares From PIPE Deal →

For everyday investors, this is a textbook securities fraud allegation: company says things look great, reality turns out to be different, stock drops, lawyers get involved. Whether or not the allegations ultimately hold up in court is a separate question, but the case signals serious scrutiny of how Aardvark communicated the state of ARD-101's development to the public.

If you purchased Aardvark common stock during the relevant Class Period, you have until October 13, 2026, to apply to become a lead plaintiff in the case. Being a lead plaintiff means you'd represent the broader group of affected investors — it doesn't affect your ability to recover potential damages either way. Investors interested in the case or their potential rights should consult a securities attorney to understand their options.

Continue reading at PR Newswire.